



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/598,777

09/11/2006

Anja Fecher

66535.000013

1177

21967

7590

12/08/2009

HUNTON & WILLIAMS LLP
INTELLECTUAL PROPERTY DEPARTMENT
1900 K STREET, N.W.
SUITE 1200
WASHINGTON, DC 20006-1109

EXAMINER

DESAI, RITA J

ART UNIT

PAPER NUMBER

1625

MAIL DATE

DELIVERY MODE

12/08/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Examiner-Initiated Interview Summary	Application No. 10/598,777	Applicant(s) FECHER ET AL.	
	Examiner Rita J. Desai	Art Unit 1625	

All Participants:

(1) Rita J. Desai.

(2) Jeff Vockrodt.

Date of Interview: 4 December 2009

Type of Interview:
☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)
Exhibit Shown or Demonstrated: ☐ Yes ☐ No
If Yes, provide a brief description: _____

Status of Application: pending

(3) _____

(4) _____

Time: _____

Part I.

Rejection(s) discussed:

Claims discussed:
all

Prior art documents discussed:
WO and US documents

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

The examiner and the attorney discussed potential rejections. the examiner explained the 112 2nd para for C0-C5 alkylcarbonyl, C0- carbonyl would be C=O only and chemically not possible.

The provisoes because of art make the C1-C5 alkoxycarbonyl groups also obvious, recommended deleting it.

Claims 13 had the term medicament comprising without any other ingredient. the examiner suggested changing it to pharmaceutical composition with the carrier as given in claim 14.

Delete claim 18 and amend claim 15 to read the antogonizing as given on page 69. (delete preventing and treating)

Part III.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

/Rita J. Desai/
Primary Examiner, Art Unit 1625

(Applicant/Applicant's Representative Signature – if appropriate)